MX2024004025A - Compuesto cíclico fusionado de cuatro miembros y método de preparación y uso de este. - Google Patents
Compuesto cíclico fusionado de cuatro miembros y método de preparación y uso de este.Info
- Publication number
- MX2024004025A MX2024004025A MX2024004025A MX2024004025A MX2024004025A MX 2024004025 A MX2024004025 A MX 2024004025A MX 2024004025 A MX2024004025 A MX 2024004025A MX 2024004025 A MX2024004025 A MX 2024004025A MX 2024004025 A MX2024004025 A MX 2024004025A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- fused ring
- membered fused
- ring compound
- protein
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 abstract 1
- 101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 abstract 1
- 102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/22—Eight-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111161691 | 2021-09-30 | ||
| PCT/CN2022/122536 WO2023051681A1 (zh) | 2021-09-30 | 2022-09-29 | 四元稠环类化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004025A true MX2024004025A (es) | 2024-05-31 |
Family
ID=85781355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004025A MX2024004025A (es) | 2021-09-30 | 2022-09-29 | Compuesto cíclico fusionado de cuatro miembros y método de preparación y uso de este. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240400582A1 (https=) |
| EP (1) | EP4410779A4 (https=) |
| JP (1) | JP2024534707A (https=) |
| KR (1) | KR20240089224A (https=) |
| CN (1) | CN118139849A (https=) |
| AU (1) | AU2022355393A1 (https=) |
| CA (1) | CA3234312A1 (https=) |
| IL (1) | IL311791A (https=) |
| MX (1) | MX2024004025A (https=) |
| TW (1) | TW202330547A (https=) |
| WO (1) | WO2023051681A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0003476D0 (sv) * | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| CN103113355B (zh) * | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
| CN109790144A (zh) * | 2016-04-29 | 2019-05-21 | 爱仕达生物技术有限责任公司 | 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂 |
| US11649218B2 (en) * | 2018-03-09 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
-
2022
- 2022-09-29 EP EP22875063.4A patent/EP4410779A4/en active Pending
- 2022-09-29 MX MX2024004025A patent/MX2024004025A/es unknown
- 2022-09-29 WO PCT/CN2022/122536 patent/WO2023051681A1/zh not_active Ceased
- 2022-09-29 US US18/697,312 patent/US20240400582A1/en active Pending
- 2022-09-29 KR KR1020247014535A patent/KR20240089224A/ko active Pending
- 2022-09-29 IL IL311791A patent/IL311791A/en unknown
- 2022-09-29 CA CA3234312A patent/CA3234312A1/en active Pending
- 2022-09-29 CN CN202280064600.7A patent/CN118139849A/zh active Pending
- 2022-09-29 AU AU2022355393A patent/AU2022355393A1/en active Pending
- 2022-09-29 JP JP2024543428A patent/JP2024534707A/ja active Pending
- 2022-09-30 TW TW111137341A patent/TW202330547A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4410779A4 (en) | 2025-07-30 |
| TW202330547A (zh) | 2023-08-01 |
| CN118139849A (zh) | 2024-06-04 |
| IL311791A (en) | 2024-05-01 |
| WO2023051681A1 (zh) | 2023-04-06 |
| AU2022355393A1 (en) | 2024-05-09 |
| CA3234312A1 (en) | 2023-04-06 |
| US20240400582A1 (en) | 2024-12-05 |
| JP2024534707A (ja) | 2024-09-20 |
| EP4410779A1 (en) | 2024-08-07 |
| KR20240089224A (ko) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| UA106057C2 (uk) | Спосіб одержання сполук дигідроінденаміду, фармацевтична композиція, що містить дані сполуки, та їх застосування як інгібітора протеїнкінази | |
| JOP20200277B1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| BR112015014222A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica | |
| MX2022005732A (es) | Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina. | |
| DOP2010000343A (es) | Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina | |
| EA201591339A1 (ru) | Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы | |
| CR20200625A (es) | Compuestos | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
| CO2020004669A2 (es) | Derivados de bencimidazol y sus usos | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| BR112022002222A2 (pt) | Derivados de quinolina como inibidores de proteínas quinases | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
| MX2024004025A (es) | Compuesto cíclico fusionado de cuatro miembros y método de preparación y uso de este. | |
| CO2025012210A2 (es) | Polimorfo como inhibidor de la proteína quinasa mek, método de preparación y uso del mismo | |
| MX2023004533A (es) | Formulaciones de anticuerpos anti-siglec-8. | |
| BR112021020405A2 (pt) | Benzo- e pirido-pirazóis como inibidores de proteína quinase | |
| MX2022011354A (es) | Compuestos de pirimidina fusionados como moduladores de kcc2. | |
| MX2025011499A (es) | Forma de cristal de sal de compuesto de anillo fusionado cuaternario, y método de preparación y uso del mismo | |
| BR112021020027A2 (pt) | Compostos, composições e métodos |